Hodgkin disease: prognostic factors and treatment strategies.

PubWeight™: 0.86‹?›

🔗 View Article (PMID 10975546)

Published in Curr Opin Oncol on September 01, 2000

Authors

A Josting1, J Wolf, V Diehl

Author Affiliations

1: First Department of Internal Medicine, University Hospital Cologne, Germany.

Articles by these authors

Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis. Proc Natl Acad Sci U S A (1968) 8.67

Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science (1967) 8.62

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med (1998) 8.24

Molecular cloning and characterization of human papilloma virus DNA derived from a laryngeal papilloma. J Virol (1982) 5.49

Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med (1996) 4.28

Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. J Natl Cancer Inst (1970) 3.94

Occurrence of Epstein-Barr virus genomes in human lymphoblastoid cell lines. Nat New Biol (1972) 3.84

Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol (1998) 3.64

Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature (1982) 3.26

Relationship between nasopharyngeal colonization and the development of otitis media in children. Tonawanda/Williamsville Pediatrics. J Infect Dis (1997) 3.11

Demonstration of a herpes group virus in cultures of peripheral leukocytes from patients with infectious mononucleosis. J Virol (1968) 3.09

Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. J Natl Cancer Inst (1969) 3.07

Letter: Possible person-to-person transmission of Creutzfeldt-Jakob disease. N Engl J Med (1974) 3.03

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood (1998) 2.83

E-cadherin regulates cell growth by modulating proliferation-dependent beta-catenin transcriptional activity. J Cell Biol (2001) 2.72

Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood (1999) 2.56

Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population. Int J Cancer (1982) 2.51

Size and albedo of Kuiper belt object 55636 from a stellar occultation. Nature (2010) 2.49

European Code Against Cancer and scientific justification: third version (2003). Ann Oncol (2003) 2.17

Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. Virology (1984) 2.13

Comparative study of cultured Burkitt tumor cells by immunofluorescence, autoradiography, and electron microscopy. J Virol (1967) 2.07

Detection of C trachomatis in urogenital specimens by polymerase chain reaction. Genitourin Med (1991) 1.97

Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol (2006) 1.74

Relation between Epstein-- Barr viral and cell membrane immunofluorescence in Burkitt tumor cells. II. Comparison of cells and sera from patients with Burkitt's lymphoma and infectious mononucleosis. J Exp Med (1968) 1.71

Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment. Ann Oncol (2001) 1.70

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol (2009) 1.68

Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis (1996) 1.68

Nasopharyngeal colonization with nontypeable Haemophilus influenzae and recurrent otitis media. Tonawanda/Williamsville Pediatrics. J Infect Dis (1994) 1.65

Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group. Ann Oncol (2004) 1.62

Immunophenotyping of low-grade B-cell lymphoma in blood and bone marrow: poor correlation between immunophenotype and cytological/histological classification. Br J Haematol (1993) 1.55

Epidemiology of nasopharyngeal colonization with nontypeable Haemophilus influenzae in the first 2 years of life. J Infect Dis (1995) 1.55

The influence of suspended particles on the acute toxicity of 2-chloro-4-nitro-aniline, cadmium, and pentachlorophenol on the valve movement response of the zebra mussel (Dreissena polymorpha). Arch Environ Contam Toxicol (2001) 1.52

Characteristics of Hodgkin's disease-derived cell lines. Cancer Treat Rep (1982) 1.51

Hodgkin's disease: establishment and characterization of four in vitro cell lies. J Cancer Res Clin Oncol (1981) 1.50

Bone marrow involvement in Hodgkin's disease: an analysis of 135 consecutive cases. German Hodgkin's Lymphoma Study Group. J Clin Oncol (1995) 1.50

Evidence for the detection of the normal counterpart of Hodgkin and Sternberg-Reed cells. Hematol Oncol (1984) 1.47

Hodgkin's disease--environmental or genetic? N Engl J Med (1995) 1.43

C-group chromosome marker in long-term leukocyte cultures. J Natl Cancer Inst (1968) 1.43

Bioelectrical impedance analysis in HIV-infected patients treated with triple antiretroviral treatment. Am J Clin Nutr (1999) 1.42

STAT3 is constitutively activated in Hodgkin cell lines. Blood (2001) 1.42

Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. J Exp Med (2000) 1.40

Correlation of chromosomal aberrations in a myeloma cell line with tumorigenicity in nude mice. Blut (1981) 1.40

Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction. J Exp Med (2000) 1.40

Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol (2000) 1.39

High platelet contamination in progenitor cell concentrates results in significantly lower CD34+ yield after immunoselection. Transfusion (2000) 1.39

Resting energy expenditure, weight loss, and altered body composition in HIV infection. Nutrition (1996) 1.38

Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient. Blood (1996) 1.36

The 'accelerator hypothesis': relationship between weight, height, body mass index and age at diagnosis in a large cohort of 9,248 German and Austrian children with type 1 diabetes mellitus. Diabetologia (2005) 1.32

The pharmacokinetics of temocillin in patients with normal and impaired renal function. J Antimicrob Chemother (1983) 1.30

A powerful DNA extraction method and PCR for detection of microsporidia in clinical stool specimens. Clin Diagn Lab Immunol (1999) 1.26

The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene (2007) 1.23

Detection of microsporidia (Enterocytozoon bieneusi) in intestinal biopsy specimens from human immunodeficiency virus-infected patients by PCR. J Clin Microbiol (1995) 1.21

Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood (2000) 1.20

Artificial sweeteners--do they bear a carcinogenic risk? Ann Oncol (2004) 1.20

Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. Blood (1996) 1.20

Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol (2000) 1.19

Hodgkin's disease derived cell lines HDLM-2 and L-428: comparison of morphology, immunological and isoenzyme profiles. Leuk Res (1986) 1.17

The listerial exotoxins listeriolysin and phosphatidylinositol-specific phospholipase C synergize to elicit endothelial cell phosphoinositide metabolism. J Immunol (1996) 1.17

Natural course of inoperable lung cancer. Chest (1973) 1.17

Gardner's dento-maxillary stigmas in patients with familial adenomatosis coli. Br J Oral Maxillofac Surg (1986) 1.15

Exclusive breastfeeding protects against bacterial colonization and day care exposure to otitis media. Pediatrics (1997) 1.14

CMV-antigenemia in peripheral blood for the diagnosis of CMV disease in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.14

Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood (2000) 1.14

Two neoplastic cell lines with unique features derived from Hodgkin's disease. Int J Cancer (1980) 1.14

Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Res (2001) 1.14

No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol (2010) 1.13

Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease. Cancer Res (1990) 1.13

Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib. Lung Cancer (2013) 1.13

A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Gene Ther (1999) 1.12

European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood (2000) 1.12

Age, dental infections, and coronary heart disease. J Dent Res (2000) 1.12

Editing of messenger RNA precursors and of tRNAs by adenosine to inosine conversion. FEBS Lett (1999) 1.12

Male involvement in family planning: a case study spanning five generations of a south Indian family. Stud Fam Plann (1997) 1.11

Cecal volvulus in pregnancy. Am J Gastroenterol (1999) 1.11

Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759]. BMC Cancer (2005) 1.10

Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol (2005) 1.10

Radiographic signs in the temporomandibular and hand joints in patients with psoriatic arthritis. Acta Odontol Scand (1991) 1.09

Fatigue in long-term survivors of Hodgkin's lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer (2003) 1.09

Classical Hodgkin's disease. Clinical impact of the immunophenotype. Am J Pathol (1997) 1.08

Isolation of the human PC6 gene encoding the putative host protease for HIV-1 gp160 processing in CD4+ T lymphocytes. Proc Natl Acad Sci U S A (1996) 1.07

Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood (2001) 1.06

Coeliac disease in children with Type 1 diabetes mellitus: the effect of the gluten-free diet. Diabet Med (2005) 1.06

HMGI-C, a member of the high mobility group family of proteins, is expressed in hematopoietic stem cells and in leukemic cells. Leuk Lymphoma (1997) 1.06

S-cone ERGs elicited by a simple technique in normals and in tritanopes. Vision Res (1999) 1.05

Paradoxical expansion of intracranial tuberculomas during chemotherapy. J Infect (1997) 1.05

Expression of epstein-barr virus nuclear antigen 1 is associated with enhanced expression of CD25 in the Hodgkin cell line L428. J Virol (1999) 1.05

The in vivo expression of the FGF receptor FREK mRNA in avian myoblasts suggests a role in muscle growth and differentiation. Dev Biol (1995) 1.04

Neoplastic cells obtained from Hodgkin's disease are potent stimulators of human primary mixed lymphocyte cultures. J Immunol (1983) 1.03

An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. Cancer Res (1998) 1.02

L-428 nodular sclerosing Hodgkin's cell secretes a unique transforming growth factor-beta active at physiologic pH. J Clin Invest (1988) 1.01

Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol (2002) 1.01

Fibre optics transillumination in caries diagnosis. Proc Finn Dent Soc (1981) 1.01